What biomarker tests should I ask for with melanoma

According to the NCCN Guidelines for Melanoma, there are several important biomarker tests that should be considered. Here are the key recommendations:

According to the NCCN Guidelines:

1. BRAF mutation testing is one of the most important biomarker tests for melanoma, as BRAF mutations are commonly found in melanomas and can affect treatment options. The guidelines specifically mention that "BRAF mutations can cause normal cells to become cancerous" and are "most commonly found in melanomas."

2. The NCCN Guidelines recommend biomarker testing particularly for:

• Patients with advanced/metastatic disease
• Cases where targeted therapy might be considered
• Situations where clinical trial eligibility needs to be determined

The American Society of Clinical Oncology (ASCO) Guidelines also support molecular testing, particularly:

• BRAF mutation testing
• PD-L1 testing in some cases
• Additional molecular testing if clinical trial participation is being considered

Important note: The specific biomarker tests recommended for you should be determined by your healthcare team based on your individual case, including:

• The stage of your melanoma
• Whether the cancer is localized or has spread
• Your potential treatment options

Always consult with your healthcare provider about which specific biomarker tests are appropriate for your situation, as testing recommendations can vary based on individual circumstances and disease characteristics.